Slides
Page 1
Q3 2026 Interim Management Statement 0 4 N o v e m b e r 2 0 2 6 Hugh McGuire Chief Executive Officer Mark Garvey Chief Financial Officer
Page 2
I M P O R T A N T N O T I C E This presentation contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this presentation. Due to the inherent uncertainties, including both economic and business risk factors underlying such forward-looking information, actual results may differ materially from those expressed or implied by these forward- looking statements. The Directors undertake no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events, or otherwise. 2 | Glanbia PLC Q3 2026 IMS Presentation
Page 3
Q 3 2 0 2 6 H I G H L I G H T S 1 Like-for-like (“LFL”) revenue growth shown on a constant currency basis. 2 Adjusted Earnings Per Share (“EPS”) on a constant currency basis. 4 | Glanbia PLC Q3 2026 IMS Presentation Strong YTD Q3 performance with volume growth across all three segments PN LFL revenue1 +18.0% driven by strong growth in Optimum Nutrition (+25.8%) H&N LFL revenue1 +9.8% with strong volume growth driven by demand across end-use markets Continued momentum in DN with strong growth in protein solutions predominantly driven by pricing Wendy Chang Smith appointed CFO Designate, effective as CFO and Executive Director from 31 March 2027 FY26 adjusted EPS2 growth upgraded to a range of 22% to 24%
Page 4
• Q3 YTD LFL revenue2 +18.0% • Volume +4.3% driven by accelerating category growth, market share gains, new distribution and innovation • Pricing +13.7% driven by price increases implemented in the last 12 months • Q3 LFL revenue2 +19.8% (volume -4.7%, price +24.5%) • Optimum Nutrition Q3 LFL revenue +26.9% (volume +0.8%, price +26.1%) and L13W US consumption3 +22.9% • Sustained investment in Optimum Nutrition, helping to drive brand awareness, market share gains and reinforce consumer loyalty 4 | Glanbia PLC Q3 2026 IMS Presentation 1 Revenue growth shown on a constant currency basis versus Q3 2025. 2 LFL revenue growth shown on a constant currency basis. 3 Consumption based on US measured channels for the 13-week period to 3 October 2026. PERFORMANCE NUTRITION (PN) Strong year-to-date performance led by Optimum Nutrition Total revenue Q3 YTD1 +8.5% Volume +4.3% Price +13.7% Disposals (9.5%) % of PN Revenue LFL Revenue Growth2 60% 40% +11.8% +28.3% Americas International
Page 5
HEALTH & NUTRITION (H&N) Continued strong volume growth momentum driven by demand in end-use markets 5 | Glanbia PLC Q3 2026 IMS Presentation • H&N LFL2 revenue +9.8% • Volume +11.5% driven by continued strong growth across core end- use markets of Active Nutrition, Functional Beverages and VMS • Pricing -1.7% driven by some tariff refunds and volume rebates to customers • Continued progress on integration of recent acquisitions and capacity expansions across the US, China and Europe Total revenue Q3 YTD1 +12.8% Volume +11.5% Price (1.7%) Acquisitions +3.0% 1 Revenue growth shown on a constant currency basis versus Q3 2025. 2 LFL revenue growth shown on a constant currency basis.
Page 6
DAIRY NUTRITION (DN) Strong performance through volume and pricing in Protein Solutions 6 | Glanbia PLC Q3 2026 IMS Presentation • LFL2 revenue +2.1% • Volume +1.4% driven by good demand for protein solutions and bioactives with demand for high-end whey proteins remaining robust • Pricing +0.7% reflects strong pricing growth in whey protein solutions, somewhat offset by lower cheese markets Total revenue Q3 YTD1 +2.1% Volume +1.4% Price +0.7% 1 Revenue growth shown on a constant currency basis versus Q3 2025. 2 LFL revenue growth shown on a constant currency basis.
Page 7
STRONG BALANCE SHEET Net Debt $704m Total committed facilities of $1.3bn D E B T €100m returned via share buyback programme €102m returned in dividends S H A R E H O L D E R R E T U R N S FY26 capex expected to be $100m – $110m C A P I T A L E X P E N D I T U R E 7 | Glanbia PLC Q3 2026 IMS Presentation
Page 8
FY26 OUTLOOK UPGRADED 8 | Glanbia PLC Q3 2026 IMS Presentation 1 On a constant currency basis. H&N Revenue growth: +8-10% EBITDA margin: 17-19% PN Revenue growth: +16-17% EBITDA margin progression DN EBITDA in a range of $175-180m Adj. EPS1 growth 22% - 24% OCF Conversion 85%+ FY26 OUTLOOK AHEAD OF MEDIUM -TERM ALGORITHM
Page 9
A P E R F O R M A N C E D R I V E N P U R P O S E L E D G L O B A L N U T R I T I O N C O M P A N Y 9 | Glanbia PLC Q3 2026 IMS Presentation
Page 10
A P P E N D I C E S A 10 | Glanbia PLC Q3 2026 IMS Presentation
Page 11
QUARTERLY REVENUE TRENDS YTD 2026 results summary (pre-exceptional)) Revenue Progression YTD 2026 versus YTD 2025 Constant Currency Movement Volume Price Like-for-like (LFL) Acquisitions / (disposals) Total Constant Currency Performance Nutrition 4.3% 13.7% 18.0% (9.5%) 8.5% Health & Nutrition 11.5% (1.7%) 9.8% 3.0% 12.8% Dairy Nutrition 1.4% 0.7% 2.1% - 2.1% Group Total 4.2% 5.7% 9.9% (3.2%) 6.7% Q3 2026 results summary (pre-exceptional)) Revenue Progression Q3 2026 versus Q3 2025 Constant Currency Movement Volume Price Like-for-like (LFL) Acquisitions / (disposals) Total Constant Currency Performance Nutrition (4.7%) 24.5% 19.8% (8.1%) 11.7% Health & Nutrition 6.1% (0.9%) 5.3% 1.9% 7.2% Dairy Nutrition (4.8%) 3.6% (1.2%) - (1.2%) Group Total (2.9%) 12.2% 9.3% (3.2%) 6.1% 11 | Glanbia PLC Q3 2026 IMS Presentation